Losartan potassium/Hydrochlorothiazide

AssetAlso called losartan potassium (+) hydrochlorothiazide, Hyzaar, MK954A, MK0954A

Angiotensin II receptor antagonist combined with a thiazide diuretic to lower blood pressure.

Stage
Approved
Modality
Small molecule
Target
Not known
7
Indications
31
Trials
3
Developers

Approved by the FDA on Apr 28, 1995 (NDA020387). FDA

Indications

7
  • Hypertension

    Approved, FDA

  • Left ventricular hypertrophy

    Approved, FDA

  • Stroke

    Approved, FDA

4 more

In the full profile

  • Target and mechanism1
  • Owner and partners3
  • Trials31
  • Competitors12
  • Aging relevance1

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets